Optimizing Androgen Deprivation Therapy (ADT) in Advanced Prostate Cancer
March 2, 2023
March 2, 2024
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Purdue University and Simumetrix.
This activity is supported in part by an independent education grant from Pfizer, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of Oncology, Urology, and other Allied Health Professionals who treat Prostate Cancer patients.
This activity will cover the foundational role of ADT in advanced prostate cancer from a multidisciplinary perspective and focuses on essential differences between the GnRH agonists and antagonists, the impact of cardiovascular risk factors, and critical patient education and engagement strategies to optimize outcomes for all patient populations.
Upon completion of this activity, participants should be better able to:
- Outline the role of Androgen Deprivation Therapy (ADT) from a multidisciplinary perspective in Advanced Prostate Cancer, which includes a differentiation between the clinical significance of GnRH agonists verses GnRH antagonists and potential medication adherence issues with these drugs (e.g., parenteral vs oral formulations).
- Describe ways to increase awareness and mitigation of both ADT cardiovascular risk factors and barriers to the delivery of equitable prostate cancer care with identification of opportunities to improve this treatment across diverse and minority populations.
- Implement a proactive patient engagement, education, and training strategy to facilitate better medication adherence (oral vs parenteral), self-identification and prompt reporting of ADT cardiovascular risk factors, and clinician identification of unique needs and preferences of diverse and minority individuals.
Dr. Neeraj Agarwal
Salt Lake City, Utah
Dr. Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an internationally recognized physician scientist in the field of genitourinary cancers. He is the overall study chair of multiple Phase I/II and Phase III trials, and serves as a steering committee member of numerous other trials. He has received SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. After receiving his medical training at the All India Institute of Medical Sciences in New Delhi, he completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, followed by a hematology-oncology fellowship at HCI.
Dr. Agarwal has authored more than 350 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration and leads early therapeutics in the SWOG genitourinary cancers committee. He holds numerous scientific communications leadership roles, including chief editor of the ASCO Daily News, specialty editor for ASCO’s cancer.net site, and editorial board member of several journals, including Journal of Clinical Oncology. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel. Recently, Dr. Agarwal was appointed as the Senior Director for Clinical Research Innovation, directly reporting to the cancer center director at the Huntsman Cancer Institute.
Dr. Alicia Morgans
Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation and the Department of Defense. She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association and is a member of the cardio-oncology committee of the American Heart Association. Since 2016, she has been President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University, College of Pharmacy and Simumetrix. The Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Purdue University College of Pharmacy designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Conflicts of Interest
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
- Neeraj Agarwal, MD
- Consultant: Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics
- Research Funding: Astra Zeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon
- Alicia Morgans, MD, MPH
- Consultant: Astellas, AAA, AstraZeneca, Bayer, Janssen, Debdreon, Exelixis, Myovant, Pfizer, Novartis, Sanofi
- Research Funding: Astellas, Bayer, Debdreon, Myovant, Pfizer, Sanofi
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Simumetrix staff, ArcheMedx staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Certificates will be available to the participant to claim after completing both modules, passing the post-tests and submitting the evaluation.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Purdue University requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected].